Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved EvkeezaTM (evinacumab-dgnb) as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat adult and pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). Evkeeza is the first FDA-approved treatment that binds to and blocks the function of angiopoietin-like 3 (ANGPTL3), a protein that plays a key role in lipid metabolism.
The window for nominations to NLA and Chapter leadership positions is now open through February 28, 2021. Open positions include:
National Lipid Association positions include:
- At-Large Board Member (up to 7)
Chapter positions include:
- At-Large Board Member (up to 5)
For more information and to nominate your colleagues, visit www.lipid.org/nominate.
JACKSONVILLE, Fla. – (January 6, 2021) -- The National Lipid Association (NLA) is proud to announce that it has achieved reaccreditation status from Joint Accreditation for Interprofessional Continuing Education for a new six-year term through November 2026. This recent reaccreditation enables the NLA to continue development of medical education for the entire healthcare team and maintain its reputation for delivering the highest quality education to its membership and beyond.